COMMUNIQUÉS West-GlobeNewswire

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
21/05/2026
– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant – – Data underscoring unique aspects of [...]
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
21/05/2026
Normalization of free light chains occurred by day 15 across all doses 100% of patients achieved a hematologic complete response (CR) at the highest tested dose Majority of patients with renal or cardiac involvement [...]
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
21/05/2026
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract featuring pooled cardiac safety data for its lead drug candidate [...]
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
21/05/2026
Presentations to cover progress across Eikon’s most advanced clinical-stage programs Updated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lung cancer (“NSCLC [...]
Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical Oncology Annual Meeting 2026
21/05/2026
Phase 1 Data Shows a 43% Overall Response Rate at the Recommended Phase 2 Dose and Durable Responses Exceeding One Year and Ongoing, with a Favorable Safety Profile Anti-Tumor Activity Seen Across ACC Subtypes and [...]
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
21/05/2026
Preliminary mPFS of 15.2 months; mDOR not reached Robust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastases ORR 60% in patients with a broad spectrum of EGFR-NCMs, including PACC Dose [...]
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
21/05/2026
Cash Runway Extended to Finance the Parkinson’s Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the " [...]
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
21/05/2026
Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Combined results evaluating AKY-2519 across several B7-H3 expressing tumor types, including metastatic [...]
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
21/05/2026
Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. ( [...]
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
21/05/2026
ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multiple CR-001 clinical [...]
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
21/05/2026
In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse events Activity of the combined regimen across all dose [...]
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
21/05/2026
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody [...]
NANOBIOTIX annonce les modalites definitives de son offre globale sursouscrite a hauteur de 85 millions d’euros
21/05/2026
PARIS et CAMBRIDGE, Mass., 21 mai 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – « Nanobiotix » ou la « Société »), une société de biotechnologie au stade clinique et en phase avancée qui développe [...]
GENFIT : Information financière du premier trimestre 2026 et point sur les activités de la Société
21/05/2026
Trésorerie et équivalents de trésorerie s’élevant à 136,1 millions d’euros au 31 mars 2026 Chiffre d’affaires de 9,6 millions d’euros pour les trois premiers mois de 2026, provenant des redevances issues des ventes d’ [...]
GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update
21/05/2026
Cash and cash equivalents totaled €136.1 million as of March 31, 2026 €9.6 million in revenue for the first three months of 2026, from royalties on Ipsen’s sales of Iqirvo® (elafibranor) Positive momentum across all [...]
TME PHARMA ANNONCE LA CONVOCATION DE L'ASSEMBLÉE GÉNÉRALE ANNUELLE DES ACTIONNAIRES DE 2026
21/05/2026
TME PHARMA ANNONCE LA CONVOCATION DE L'ASSEMBLÉE GÉNÉRALE ANNUELLE DES ACTIONNAIRES DE 2026 Berlin, Allemagne, le 21 mai 2026, 18 h 00 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), Une société de biotechnologie [...]
TME PHARMA ANNOUNCES CONVOCATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
21/05/2026
TME PHARMA ANNOUNCES CONVOCATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS Berlin, Germany , May 21, 2026, 18.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company [...]
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
21/05/2026
WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to [...]
The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults
21/05/2026
The olanzapine long-acting injectable ( TEV-’749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation 1 administered every four weeks. If approved, TEV-‘749 could help fill a significant [...]

Pages